€25.9m market cap
€1.15 last close
Pixium Vision develops retinal implants for patients with severe vision loss. PRIMA, a wireless sub-retinal implant, designed for Dry-ARMD patients, is in a human clinical stage in Europe and is recruiting patients in its US feasibility study.
Investment summary
Pixium Vision is developing the Prima wireless photovoltaic sub-retinal implant, which transforms images into electrical signals to elicit a form of central visual perception in patients with severe retinal disease. Positive data from its EU Prima feasibility study in patients with atrophic dry age-related macular degeneration were reported in Q119. All five implantations were followed by successful activations and reported light perception in areas where there had been none prior to implantation. Pixium plans to start implantations in a US Prima feasibility study in H219 and to start an EU pivotal study by mid-2020 that we expect will incorporate improved augmented reality glasses within the Prima system.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (fd) (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 2.5 | (11.7) | (13.5) | (102.07) | N/A | N/A |
| 2018A | 1.6 | (6.1) | (8.1) | (43.67) | N/A | N/A |
| 2019E | 1.9 | (9.4) | (11.3) | (50.49) | N/A | N/A |
| 2020E | 0.0 | (15.9) | (20.9) | (92.99) | N/A | N/A |
| Last updated on 16/09/2019 | ||||||
Industry outlook
Pixium held €10.2m in gross cash at 30 June 2019, which we estimate will fund operations into Q220. Prima has been designed and being evaluated in clinical studies as a potential treatment option for dry AMD, a common disease in aging population and a significant unmet medical need.
Last updated on 16/09/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 5.3 |
| Forecast gearing ratio (%) | 501 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Lloyd Diamond | CEO |
| Didier Laurens | CFO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma